INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune dysfunction to fight disease. The Company’s ...
When Gleevec was invented, or when it came out, that was a game-changer for patients with GIST, because they previously had ...
INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of ...
Cogent Biosciences (COGT) shares have surged after pivotal bezuclastinib data in imatinib-resistant aGIST. Read the latest ...
BostonGene has won four awards in the Research & Development, Product Launches, and Innovation categories in the 2025 ...
Mesoblast announced that an independent, peer-reviewed meta-analysis presented at the 67th ASH Annual Meeting found its remestemcel-L outperformed ruxolitinib in complete and overall remission for ...
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed comparative analysis of efficacy ...
Merhi reportedly explained a procedure still considered experimental: an injection of platelet-rich plasma, or PRP, into the ...
In this video, Gailen D. Marshall Jr., MD, PhD, chair of allergy and immunology at University of Mississippi Medical Center, discusses the clinical development of the nanobody compound lunsekimig for ...
This article explores how researchers are using spatially resolved methods to explore diverse biological processes from ...
The axolotl, a type of salamander that stays in the tadpole form throughout its life, is a master of regeneration. Axolotls ...
CURE recently sat down with Dr. Ajay Gupta of the Roswell Park Comprehensive Cancer Center in Buffalo, New York, to discuss what patients should do if they have recently received a diagnosis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback